Theralase Technologies Inc. V.TLT

Timeframe for evaluation

[BencrosMum]

The patients who responded to the Study Treatment are currently under medical review to assess the cause of the suspicious cystoscopy by directed bladder biopsy and the cause of the positive or suspicious cytology by repeating the urine cytology analysis.
 

Any ideas on how long this should take? I understand having to wait on overloaded hospitals and medical equipment, especially if escalating to CT.
Could they already have results or is this weeks/months away?

[riverrrow]

A friend of mine has had one and possibly two ct scans performed in the last two months in Ontario for a non life threatening ongoing condition. TLT's should have all been processed by now.

[skys1]

I suspect positive news will come a few days before the AGM. They are managing the timeing of news, such as the release the Q financials after the market close on a Friday afternoon. I wouldn't be surprised if they already have it. 

[NeilPaert74]

I think Eoga sniffed it out a while back, somethin' formal with Roswell Park. Maybe some solid data and a RP paid for phase 1 on nsclc announced? 

[skys1]

Neil, I believe it will be at least some positive updates on the Ph 2 patients exam results, Hopefully a nice jump in CR %. Also, could be something on Roswll as you suggest. I think it's a little early to expect or hope for something from U of M.

[NeilPaert74]

I think the good Dr. Coombs mentioned an update in Oct. So not by AGM time but soon after.

[greaterfoolFred]

I must admit that I don't know as much about this company as I should, but it seems to me that the key to any application beyond topical is the toxicology of TLD-1433.  The company should have this well characterized by now.  Does anyone here know how far they have gotten?  Have they published anything about animal or human tox studies? Good luck all.

[greaterfoolFred]

Well, a Google search made quick work of that question.  From a 2015 Theralase newws release; "In the rat toxicology study, the No Observed Adverse Events Level (“NOAEL”) IV limit was determined to be 1.2 mg/mL (6 mg/kg)." Not bad at all.

[skys1]

greaterfool, Go to the Company website, check the results of their Ph 1 trial on NMIBC. The primary endpoint was safety. It was so successful it was closed early.

[greaterfoolFred]

Yes, but for NMIBC the application is topical; very little enters the bloodstream.  For the treatment of covid, or internal cancers the drug will have to be given by iv into the bloodstream.  Dr. Coombs is talking about efficacy in the nanomolar range.  TLD-1433 has a molecular weight of about 1000, so for example, 100 nanomolar works out to about 100 ug/L. So the dose level in an

[Hempdoc]

I will leave the math to you. ; )... the key to our compound's success will be in the development of a practical/effective form of systemic therapy that can be used in the "outpatient setting", which is still the big window of opportunity.  The molecular size & solubility characteristics of our compound should allow for a nebulized/inhaled form of treatment (given via a home